Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer.

ABSTRACT:

Background

Bladder cancer represents a heterogeneous disease with distinct clinical challenges. Non-muscle invasive bladder cancer (NMIBC) typically presents as indolent and slow-growing, yet a critical clinical challenge remains: identifying which patients will progress to muscle-invasive disease requiring radical interventions. Early detection of progression propensity is essential, as once muscle invasion occurs, the risk of distant metastasis increases substantially, and treatment shifts from conservative TURBT (Transurethral Resection of Bladder Tumor) to aggressive surgical interventions with significant morbidity. Current risk stratification methods fail to adequately predict this transition in approximately 30% of cases, highlighting the urgent need for more accurate progno

SUBMITTER: N S 

PROVIDER: S-EPMC12096726 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature